AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...

The FDA approved benralizumab (Fasenra) for adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

The active ingredient in Fasenra is a medicine called benralizumab, which works by binding to eosinophils. This reduces the number of eosinophils in the lungs, which reduces the amount of swelling.

In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.

AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...

4 FASENRA (benralizumab) is currently approved in more than 80 countries, including the US, EU, Japan, and China.10-13 FASENRA has been prescribed to over 130,000 patients globally.20 FASENRA is ...

New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids AstraZeneca's Fasenra ...

The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.

September 18, 2024--(BUSINESS WIRE)--AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

The Food and Drug Administration (FDA) has approved Fasenra ® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). Study participants were ...

More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.